Nuvectis NXP200 wins Breakthrough Therapy Designation in China for HGG
Nuvectis Pharma has announced that NXP200, its oral, brain-penetrant BRAF inhibitor, has received Breakthrough Therapy Designation (BTD) from China's Centre for Drug Evaluation (CDE) for patients with BRAF V600-mutant, recurrent or progressive high-grade glioma. The designation was granted to Haisco Pharmaceutical Group, which retains Greater China rights to the compound, and reflects clinical activity observed to date in heavily pre-treated patients, including those who had already received an earlier-generation BRAF inhibitor.
Nuvectis in-licensed exclusive worldwide, ex-Greater China rights to NXP200 from Haisco in June 2026. The NASDAQ-listed company is now advancing the asset toward a US Investigational New Drug (IND) submission, which it says it expects to file in the fourth quarter of 2026.
What makes NXP200 distinct
NXP200 is described by the company as a "paradox-breaker" BRAF inhibitor. First-generation BRAF inhibitors, including vemurafenib and dabrafenib, are associated with paradoxical activation of the MAPK pathway in RAS-mutant cells, which can lead to resistance and, in some cases, secondary tumour growth. NXP200 is engineered to block the BRAF pathway without triggering this effect. The compound is also designed for central nervous system penetration, a property of particular relevance in high-grade glioma, where the blood-brain barrier substantially limits the activity of many targeted agents.
Ron Bentsur, chairman and chief executive of Nuvectis, said the Chinese designation "underscores the compelling clinical activity observed to date with NXP200 in patients with recurrent or progressive BRAF V600-mutant high-grade glioma," while noting that US development activities are running in parallel.
Market context and competitive landscape
High-grade glioma, including glioblastoma and grade 3 to 4 astrocytoma, remains one of oncology's most refractory disease areas. BRAF V600 mutations occur in a clinically meaningful proportion of paediatric and young adult glioma cases, making targeted inhibition an active area of development. Established agents such as dabrafenib plus trametinib have shown activity in BRAF V600-mutant glioma, and their combination received FDA accelerated approval in this setting. The paradox-breaker class aims to address resistance mechanisms that limit the durability of those responses, particularly in patients who have already progressed on first-generation BRAF therapy.
China's BTD is broadly analogous to the FDA's Breakthrough Therapy designation in offering potential for expedited review and more intensive regulatory interaction. The designation does not, however, guarantee approval, and Nuvectis has not yet published a full clinical dataset for NXP200 in glioma. Investors and clinicians will be watching for the US IND filing later this year, which would open a path toward a formal US clinical programme and, ultimately, the kind of controlled trial data needed to support approval on either side of the Pacific. The dual-track approach, with Haisco driving Chinese development and Nuvectis owning ex-Greater China rights, is a licensing structure that has become common in the sector as US companies seek to leverage Chinese clinical infrastructure while retaining commercial upside in larger Western markets.